Viacheslav Kudriavskii

Mr. Viacheslav Kudriavskii

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2024 in Biochemistry (Moscow)
Verified
Journal Article
Closed access
PDF file
VKViacheslav Kudriavskii
Viacheslav Kudriavskii
AGAnton O. Goncharov
Anton O. Goncharov
AEArtem V. Eremeev
Artem V. Eremeev
EREvgenii S. Ruchko
Evgenii S. Ruchko
VVVladimir A. Veselovsky
Vladimir A. Veselovsky
AKAnna A. Kliuchnikova
Anna A. Kliuchnikova
Expansion of CAG repeats in certain genes is a known cause of several neurodegenerative diseases, but exact mechanism behind this is not yet fully understood. It is believed that the double-stranded RNA regions formed by CAG repeats could be harmful to the cell. This study aimed to test the hypothesis that these RNA regions might potentially interfere with ADAR RNA editing enzymes, leading to the reduced A-to-I editing of RNA and activation of the interferon response. We studied induced pluripotent stem cells (iPSCs) derived from the patients with Huntington’s disease or ataxia type 17, as well as midbrain organoids developed from these cells. A targeted panel for next-generation sequencing was used to assess editing in the specific RNA regions. Differentiation of iPSCs into brain organoids led to increase in the ADAR2 gene expression and decrease in the expression of protein inhibitors of RNA editing. As a result, there was increase in the editing of specific ADAR2 substrates, which allowed identification of differential substrates of ADAR isoforms. However, comparison of the pathology and control groups did not show differences in the editing levels among the iPSCs. Additionally, brain organoids with 42-46 CAG repeats did not exhibit global changes. On the other hand, brain organoids with the highest number of CAG repeats in the huntingtin gene (76) showed significant decrease in the level of RNA editing of specific transcripts, potentially involving ADAR1. Notably, editing of the long non-coding RNA PWAR5 was nearly absent in this sample. It could be stated in conclusion that in most cultures with repeat expansion, the hypothesized effect on RNA editing was not confirmed.

14 May 2025 in Drug and Alcohol Dependence
Verified
Journal Article
Closed access
MTMichil Trofimov
Michil Trofimov
VKViacheslav Kudriavskii
Viacheslav Kudriavskii
LSLayal Shaheen
Layal Shaheen
EKElena Kovalenko
Elena Kovalenko
KVKate Vergasova
Kate Vergasova
ARAlexandr Rakitko
Alexandr Rakitko

Verified
Open access
VKViacheslav Kudriavskii
Viacheslav Kudriavskii
VKValeriia A. Koss
Valeriia A. Koss
VSVictoria O. Shender
Victoria O. Shender
GAGeorgij P. Arapidi
Georgij P. Arapidi
Immunotherapy has transformed cancer treatment, yet its clinical benefit remains limited in many tumors, particularly those with low mutational burden. Because most current immunotherapeutic strategies rely on neoantigen recognition, expanding the repertoire of targetable tumor-specific antigens is essential. In this review, we discuss non-canonical and therapy-induced neoantigens – derived from alternative splicing, RNA editing, transposable elements, and aberrant translation – as emerging sources of immunotherapy targets, with emphasis on their potential to improve the efficacy of current treatment approaches. We summarize recent evidence supporting the immunogenicity of corresponding neoepitopes and highlight therapy-induced antigen generation as a promising but underexplored opportunity. In particular, we focus on the impact of splicing dysregulation and chemotherapy-induced splicing alterations on neoepitope formation. We argue that integrating non-canonical and induced neoantigens into currently available immunotherapy approaches could improve antitumor efficacy and the specificity of resulting therapies, especially in tumors with limited mutational load.

9 June 2026 in Genes & Cells
Verified
Journal Article
Open access
AIAgata Ignateva
Agata Ignateva
AKAlexandr Kuznetsov
Alexandr Kuznetsov
VKViacheslav Kudriavskii
Viacheslav Kudriavskii
OAOlga Aleshikova
Olga Aleshikova
NBNataliya Babaeva
Nataliya Babaeva
GAGeorgij Arapidi
Georgij Arapidi
BACKGROUND. Ovarian adenocarcinoma is characterized by a high mortality rate due to late diagnosis and the development of resistance to standard chemotherapy. Despite the introduction of targeted therapies, the risk of recurrence remains high, highlighting the need for new therapeutic approaches. In this view, immunotherapy is a promising approach, but requires the identification of specific tumor antigens. AIM. To identify tumor antigens in ovarian adenocarcinoma that are promising for immunotherapy. METHODS. Immunopeptidome from cell lines and postoperative material of patients with ovarian adenocarcinoma were isolated using immunoaffinity chromatography followed by liquid chromatography-mass spectrometry analysis. RESULTS. In this study, we tested an affinity chromatography-based immunopeptidome isolation protocol, comparing various detergents (CHAPS, NP-40, SOD, and Triton X-100) for cell lysis, and observed no statistically significant differences in the number of identified peptides. Using NP-40, 5 peptides belonging to the proteins of cancer/testis antigens (CTA) were identified in the immunopeptidomes of postoperative material from patients with ovarian adenocarcinoma, 3 of which, according to the human protein atlas, are indeed not expressed in normal ovarian tissues. CONCLUSION. Each of the four tested detergents provides identification of unique sets of peptides. Immunopeptidome analysis allows the identification of peptides ofCTA proteins, but a larger sample of postoperative material from patients with ovarian adenocarcinoma and experimental testing of the immunogenicity of the identified peptides are needed for further research.

Verified
Journal Article
Open access
PDF file
VKViacheslav Kudriavskii
Viacheslav Kudriavskii
AKAnna Kliuchnikova
Anna Kliuchnikova
AGAnton Goncharov
Anton Goncharov
EIEkaterina Ilgisonis
Ekaterina Ilgisonis
SMSergei Moshkovskii
Sergei Moshkovskii
This paper summarizes the results of multi-year studies performed by our research team, focusing on an analysis of protein recoding mediated by messenger RNA editing by ADAR adenosine deaminases. Searching for ADAR-mediated protein recoding was performed in the central nervous system of the model organisms, fruit fly and mouse, as well as in the human proteomic datasets. The proteogenomic approach has made it possible to identify dozens of editing events in the proteome, thus validating the results of transcriptomic studies. The observed recoding events in animals, ranging from insects to mammals, mainly affect the cytoskeletal components and proteins involved in synaptic transmission. In humans, recoding changes are most often observed in the central nervous system or tumor tissues. Over 15 million editing sites have been identified in humans; only a few thousand of those can potentially yield amino acid substitutions. Using a proteogenomic approach, dozens of protein recoding sites are identified, demonstrating their origin in ADAR RNA editing. Moreover, this revealed that the level of recoding at specific sites is not directly related to the abundance of ADAR enzymes per se or their target proteins. The recoding processes probably have differential regulation of interactions at the mRNA level that is yet to be clarified.